Kyverna Therapeutics, Inc. Stock Repurchased During Period, Shares
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for the quarter ending 2024-12-31 was 0.00 shares.
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for the quarter ending 2024-09-30 was 0.00 shares.
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for the quarter ending 2024-06-30 was 0.00 shares.
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for the quarter ending 2024-03-31 was 0.00 shares.
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. stock repurchased during period, shares for fiscal 2023 was 8.13K shares.
| Period end | Stock Repurchased During Period, Shares 3 month | Stock Repurchased During Period, Shares 12 month |
|---|---|---|
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 8.13K shares 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |